Bristol-Myers Squibb Executive and Leadership Team

Brandon Taverni, the Vice President, BD and Strategic Finance, Chief Financial Officer Support Lead at Bristol-Myers Squibb, architects the financial strategies and business development initiatives that support the company's long-term growth. Overseeing strategic investments and financial planning, the Vice President, BD and Strategic Finance, Chief Financial Officer Support Lead ensures that capital allocation aligns with the organization's research and development priorities. This role involves evaluating potential partnerships and alliances that accelerate the development of new treatment options. By providing financial oversight, Brandon Taverni directly impacts the company's ability to sustain its comprehensive medication portfolio. Furthermore, the Vice President, BD and Strategic Finance, Chief Financial Officer Support Lead manages the financial reporting and analysis required to support executive decision-making. Through these efforts, Taverni secures the financial health of the organization, enabling the continued pursuit of medical breakthroughs in oncology and other therapeutic domains.

Imara Charles, the Vice President, Chief of Staff, Global Product Development and Supply at Bristol-Myers Squibb, directs the operational alignment of the global supply chain and product development pipelines. Overseeing complex manufacturing logistics, the Vice President, Chief of Staff, Global Product Development and Supply ensures that life-saving medications reach patients across diverse international markets. This leadership role involves coordinating cross-functional teams to optimize production efficiency and maintain rigorous quality standards for oncology and cardiovascular therapies. By streamlining internal processes, Imara Charles directly impacts the speed at which new treatments transition from development to commercial availability. Furthermore, the Vice President, Chief of Staff, Global Product Development and Supply manages strategic resource allocation to support the organization's expansive biopharmaceutical portfolio. Through this oversight, Charles secures the operational stability required to address significant unmet medical needs on a global scale.

Hena Abidi, the S & O Lead For Rdc People Organization Chief of Staff at Bristol-Myers Squibb, architects the strategic framework for human capital development within the research and development divisions. Managing organizational design and talent integration, the S & O Lead For Rdc People Organization Chief of Staff ensures that scientific teams possess the necessary resources to drive breakthroughs in immunoscience and virology. This role involves fostering a collaborative environment where internal capabilities align with long-term research objectives. By optimizing workforce planning, Hena Abidi directly supports the company's mission to translate complex scientific data into meaningful therapeutic advances. Furthermore, the S & O Lead For Rdc People Organization Chief of Staff facilitates communication across departments to maintain high performance standards. Through these initiatives, Abidi strengthens the organizational culture, ensuring that the company remains at the forefront of pharmaceutical innovation while addressing critical patient requirements.

Brittany Schuck, the Chief of Staff, ICV at Bristol-Myers Squibb, coordinates strategic initiatives within the Immunoscience, Cardiovascular, and Virology therapeutic domains. Overseeing the execution of high-priority projects, the Chief of Staff, ICV ensures that research efforts remain focused on addressing significant patient needs in these specialized areas. This leadership role involves managing cross-departmental workflows to accelerate the development of innovative treatments. By aligning operational goals with scientific milestones, Brittany Schuck directly contributes to the company's ability to deliver advanced therapies to global markets. Furthermore, the Chief of Staff, ICV facilitates decision-making processes that enhance the efficiency of clinical development programs. Through rigorous project management and strategic oversight, Schuck supports the organization's commitment to maintaining a robust portfolio of medications that address complex conditions, ultimately driving the company's impact on patient health outcomes worldwide.

Moses Munyua, the Groc Senior Communications Specialist & Chief Technology Officer, Emd at Bristol-Myers Squibb, directs the technological infrastructure and communication strategies for the enterprise manufacturing division. Overseeing digital transformation initiatives, the Groc Senior Communications Specialist & Chief Technology Officer, Emd ensures that manufacturing facilities utilize cutting-edge technology to maintain production excellence. This role involves integrating advanced data systems to monitor pharmaceutical manufacturing processes, thereby enhancing operational reliability. By bridging the gap between technical requirements and organizational communication, Moses Munyua directly supports the company's ability to scale production for critical medications. Furthermore, the Groc Senior Communications Specialist & Chief Technology Officer, Emd manages the deployment of new technologies that improve efficiency across the global supply chain. Through these efforts, Munyua secures the technological foundation necessary for the company to continue delivering high-quality therapeutic solutions to patients in need.

Benjamin Kingscott, the Manager, Chief Technology Officer Plant Engineering at Bristol-Myers Squibb, architects the engineering standards and technological systems for the company's manufacturing plants. Overseeing the maintenance and optimization of critical infrastructure, the Manager, Chief Technology Officer Plant Engineering ensures that production facilities operate at peak efficiency to support the global demand for prescription medications. This role involves implementing advanced engineering solutions that enhance the safety and reliability of pharmaceutical manufacturing processes. By managing technical upgrades, Benjamin Kingscott directly impacts the company's capacity to produce complex therapies consistently. Furthermore, the Manager, Chief Technology Officer Plant Engineering coordinates with cross-functional teams to ensure that plant operations align with broader corporate sustainability and quality goals. Through these technical leadership efforts, Kingscott maintains the operational integrity of the manufacturing network, enabling the organization to fulfill its mission of providing essential treatments to patients worldwide.

Nicole Costa, the Cell Therapy Development & Operations Chief of Staff at Bristol-Myers Squibb, directs the strategic operations for the company's advanced cell therapy programs. Overseeing the integration of development and manufacturing workflows, the Cell Therapy Development & Operations Chief of Staff ensures that innovative cancer immunotherapies move efficiently through the clinical pipeline. This leadership role involves managing complex operational challenges associated with personalized medicine to improve patient access. By streamlining internal processes, Nicole Costa directly supports the company's goal of delivering transformative treatments for cancer. Furthermore, the Cell Therapy Development & Operations Chief of Staff facilitates collaboration between research teams and manufacturing units to maintain high quality standards. Through these initiatives, Costa drives the operational success of the cell therapy portfolio, ensuring that the organization remains a leader in developing cutting-edge medical solutions for patients facing serious health conditions.

Sharon Tuccillo, the Senior Executive Associate To Chief Information Officer at Bristol-Myers Squibb, coordinates the strategic priorities and operational activities of the information technology division. Overseeing the administrative and functional alignment of the CIO's office, the Senior Executive Associate To Chief Information Officer ensures that digital initiatives support the company's broader biopharmaceutical research and manufacturing goals. This role involves managing complex communication flows and project tracking to enhance the efficiency of the IT department. By facilitating executive decision-making, Sharon Tuccillo directly contributes to the successful implementation of technology solutions that drive innovation across the organization. Furthermore, the Senior Executive Associate To Chief Information Officer manages stakeholder engagement to ensure that IT strategies remain responsive to the needs of the global business. Through these efforts, Tuccillo supports the technological infrastructure required for the company to maintain its competitive edge in the pharmaceutical industry.

Joshua Sugrim, the Manager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy at Bristol-Myers Squibb, directs the technical validation of manufacturing processes for CAR T cell therapies. Overseeing the scientific rigor of process development, the Manager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy ensures that production methods meet stringent regulatory and quality standards. This role involves analyzing complex data sets to optimize manufacturing consistency for personalized cancer treatments. By validating critical process parameters, Joshua Sugrim directly impacts the safety and efficacy of the company's cell therapy offerings. Furthermore, the Manager, Chief Technology Officer MSAT Process Validation - CAR T Cell Therapy collaborates with engineering and clinical teams to troubleshoot technical challenges during the scale-up phase. Through these specialized efforts, Sugrim supports the organization's commitment to delivering innovative, high-quality immunotherapies to patients with significant medical needs.

Yograj Jadav, the Manager, Chief Technology Officer MSAT Process Validation (CAR- T) at Bristol-Myers Squibb, directs the technical validation of manufacturing processes specifically for CAR-T cell therapies. Overseeing the development of robust validation protocols, the Manager, Chief Technology Officer MSAT Process Validation (CAR- T) ensures that manufacturing operations maintain the highest levels of precision and quality. This role involves conducting detailed process assessments to identify and mitigate risks in the production of personalized immunotherapies. By ensuring technical compliance, Yograj Jadav directly supports the company's ability to deliver reliable treatments to patients. Furthermore, the Manager, Chief Technology Officer MSAT Process Validation (CAR- T) coordinates with cross-functional teams to implement process improvements that enhance manufacturing efficiency. Through these technical leadership efforts, Jadav contributes to the organization's success in the competitive field of cell therapy, ensuring that scientific breakthroughs translate into consistent and effective therapeutic outcomes.